CAS: 19545-26-7; (1S,6Br,9As,11R,11Br)-1-(Methoxymethyl)-9A,11B-Dimethyl-3,6,9-Trioxo-1,6,6B,7,8,9,9A,10,11,11B-Decahydro-3H-Furo[4,3,2-De]Indeno[4,5-H]Isochromen-11-Yl Acetate

上下游产品

CAS号58053-83-1 17β-hydroxy Wor... | CAS号382-44-5 4-雄烯-11β-醇-3,17-二酮 | CAS号1035-69-4 9-去氢雄烯二酮 | CAS号2899-95-8 20-hydroxycortisol | CAS号58053-83-1 17β-hydroxy Wor...

4-雄烯-11β-醇-3,17-二酮置于吡啶,三乙烯二胺,盐酸,甲醇,Sodium Periodate,四氧化锇,三丁基膦,三(二甲氨基)甲烷,敌草腈,Camphor-10-Sulfonic Acid,双氧水,碘,4-甲基苯磺酸吡啶,碳酸氢钠,Potassium Carbonate,Potassium Hydrogencarbonate,对甲苯磺酸,甲基磺酰氯,三乙胺,N,N-二异丙基乙胺,对苯二酚,间氯过氧苯甲酸,Pyridinium Chlorochromate,2,3-二氯-5,6-二氰基-1,4-苯醌,柠檬酸,Silver(L) Oxide,Tetramethylammonium Triacetoxyborohydride体系中,用 四氢呋喃,1,4-二氧六环,甲醇,二氯甲烷,氯仿,水,溶剂黄146,乙腈,苯 用作溶剂,化学反应 316.83H,反应生成渥曼青霉素
参考文献:从氢化可的松开始的第一个化学合成渥曼青霉素的方法
标题:从氢化可的松开始的第一个化学合成渥曼青霉素的方法
摘要:渥曼青霉素(一种有效且特异性的pi 3激酶抑制剂)的第一个化学合成是通过从市售的光学纯氢化可的松开始进行的.
Doi:10.1016/0040-4039(96)01332-9

专利信息

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-2006246505-A1
优先权日:2003-09-02
标题:Modulation of the synthesis of insulin
发明人：WALTHER REINHARD
权利人:WALTHER REINHARD
摘要:The invention particularly relates to the use of substances, which modulate the activity of the proteins casein kinase II (CK II) and 14-3-3 epsilon and/or of the PcG protein EED or which influence the binding of the proteins casein kinase II (CK II) and 14-3-3 epsilon, of the PcG protein EED and/or of a fragment thereof with the protein pancreatic duodenal homeobox-1 (PDX-1) that plays a decisive roll in the glucose-induced biosynthesis of insulin, for influencing the synthesis of insulin or the provision of insulin.

专利号:EP-1546732-B1
优先权日:2002-09-03
标 题:Modulation of the synthesis of insulin
发明人：WALTHER REINHARD
权利人:UNIV ERNST MORITZ ARNDT
摘要:The invention particularly relates to the use of substances, which modulate the activity of the proteins casein kinase II (CK II) and 14-3-3 epsilon and/or of the PcG protein EED or which influence the binding of the proteins casein kinase II (CK II) and 14-3-3 epsilon, of the PcG protein EED and/or of a fragment thereof with the protein pancreatic duodenal homeobox-1 (PDX-1) that plays a decisive roll in the glucose-induced biosynthesis of insulin, for influencing the synthesis of insulin or the provision of insulin.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-10905769-B2
优先权日:2015-11-13
标 题:Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
发明人：BURKE JR TERRENCE R; HYMEL DAVID T; TSUJI KOHEI
权利人:THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
摘要:The description provides novel compounds that may serve as anticancer therapeutics. The compounds of the description bind to polo-like kinases through the polo-box domain. The peptide derivatives of the description have achieved improved efficacy in biochemical assays against Plk1. Exemplary compounds of the description include macrocyclic peptidomimetics with high affinity and selectivity for polo-like kinases, which may provide the basis for a new genre of anticancer therapeutics. Other exemplary compounds of the description include bi-valent compounds with that bind to polo-like kinases through both kinase domain and polo-box domain simultaneously by incorporating additional moieties that target Plk1 kinase domain, which significantly enhances affinitity relative and may provide the basis for a new genre of anticancer therapeutics. The description also provides methods of use, methods of preparation, compositions, and kits thereof. Further, the description provides a novel method of design and/or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.